The radiotherapy market is growing due to several factors, such as an increase in the number of new cancer cases and technological advances in hardware and software used in radiation therapy. The current international market has failed to cope with new cancer cases. In low- and middle-income countries, only 10% of the population has access to radiation therapy. As a result, there is a large gap between demand and equipment installation base, which provides a huge opportunity for the company to grow in the radiotherapy market. Expanding the radiotherapy market can save lives and achieve profitability.
Effective treatment plan
This is necessary and ongoing technology development is underway to minimize radiation exposure to healthy tissue to avoid any side effects. This goal is the driving force behind radiotherapy research and development. Software plays an increasingly important role in cancer treatment. Population growth and life expectancy increase the incidence of cancer. The software and services section includes software for treatment planning, analysis, and service that is required to maintain and effectively use radiotherapy equipment. As software products help improve physician engagement and clinical knowledge sharing, patient care management, and management of cancer clinics, radiation therapy centers, and oncology practices to improve performance, the company's software and services division is expected to grow. Companies such as Varian continue to increase their software portfolio. Software plays an increasingly important role in cancer treatment. At the same time, medical systems in almost every country are subject to severe budget constraints. As a result, healthcare providers face the challenge of achieving more goals while using fewer resources. To achieve this goal, hospitals urgently need a software platform that enables cost-effective radiation therapy. The development of effective software will improve the delivery of advanced radiation therapy in the future.
Introducing new technologies
from
Technology is another significant feature. Radiation therapy remains an important means of cancer treatment, which is a major driver of new technologies designed to improve the survival rate of cancer patients. New technologies such as proton beam therapy can be used in developed countries such as the United States, Germany and the United Kingdom due to improved reimbursement policies. Proton therapy can be used in highly sensitive tissues such as the brain, spine and ocular tumors. It is more accurate than other X-ray radiation therapies.
Advancing the technology will also help in the planning of radiation therapy.
Technological advances in prior art, such as CT imaging, have made imaging more accurate and consistent. This can better represent the tumor and contribute to better planning. Existing technologies such as IMRT, SBRT, IGRT, conformal 3D, VMAT and other techniques for radiation therapy are undergoing various advances. For example, Varian is developing a software that can be used to develop better planning tools, where statistical models can be used to calculate the quality of patient IMRT treatments. This is expected to increase the amount of IMRT used to treat cancer. IGRT is a type of radiation therapy. The study focused more on IGRT to demonstrate fewer side effects. IGRT may include electronic portal vein imaging, fluoroscopy, ultrasound, CT scan reconstruction, and respiratory gating. SBRT is also growing into an option for treating cancer. SBRT is used to escalate doses to targeted tumors, which can increase local control while limiting dose to nearby critical structures and normal tissues. This will cause minimal damage to the surrounding organization and will therefore experience strong growth during the forecast period.
Internal radiotherapy has a very low proportion in the radiotherapy market. Containing 钇90, a radioactive substance, is also an emerging technology. As of April 2015, only two manufacturers offer commercial SIRT formats. SIRT is becoming a mainstream treatment; other manufacturers are actively pursuing their marketing, leading to growth in the internal radiation therapy sector. However, SIRT has not been widely used in the UK.
Internal radiotherapy is more accurate when targeting cancer cells because it is placed near the tumor, which reduces the risk of damaging healthy tissues and organs, thereby contributing to the growth of the internal radiotherapy market.
In order to increase market share, the company continues to invest in research and development. The positive results of this intensive R&D and strategic partnership can help these companies gain significant momentum in the emerging field of radiation therapy.
Orignal From: Current status and future of radiation therapy
No comments:
Post a Comment